No Automatic Refills
C (101 MHz, CDCl 3 ) 171.09 (C), 134.80 (t, J = 23.8 Hz, CD), 133.12 (td, J = 24.8, 9.9 Hz, CD), 130.22 (td, J = 24.7, 12.5 Hz, CD), 117.87 (d, J = 85.8 C), 38.67 (CH 2 ), 38.37 (CH 2 ), 27.54 (CH 2 ), 26.86 (d, J = 16.7 Hz, CH 2 ), 22.31 (d, J = 51.3 Hz, CH 2 ), 21.72 (d, J = 4.3 Hz, CH 2 )
Novos oral Wegovy is expected to receive an FDA decision in late 2025, with Lillys oral Zepbound close behind in 2026
Results and Testimonial Disclaimer: results and outcomes described anywhere in this article, whether sourced from Telos Rx's brand-reported statistics or from named patient testimonials on the brand's site, are not typical, are not guaranteed, and individual results vary based on factors including starting weight, medical history, and program adherence, per the brand's own terms of use